HIGHLIGHTS
- who: IgE downregulation et al. from the IncTaiwan University have published the research work: IgE-neutralizing UB-221 mAb distinct from, in the Journal: (JOURNAL)
- what: The ligelizumab used in this study could legitimately represent the original ligelizumab as far as the IgE binding or IgE neutralization is concerned. This trial was designed and sponsored by UBP and was conducted according to Good Clinical Practice at 2 sites in Taiwan.
- how: The validity of the PBMC IgE method was tested in the UB-221-versus-omalizumab study at concentrations of 1 3 and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.